Professional Documents
Culture Documents
MAC3761 - Exam Question Paper - 10 Nov 2023
MAC3761 - Exam Question Paper - 10 Nov 2023
Oct/Nov 2023
MAC3761
Management Accounting III
100 Marks
Duration: 3 Hours (writing time)
EXAMINATION PANEL AS APPOINTED BY THE DEPARTMENT
Closed-book examination.
The examination question paper remains the property of the University of South Africa and may not be
distributed beyond its intended use for this examination.
THIS PAPER CONSISTS OF FIFTEEN (15) PAGES IN TOTAL (INCLUDING THE INSTRUCTIONS).
IMPORTANT INSTRUCTIONS:
1. This is a closed-book exam. You are not allowed to copy from or consult any sources,
including for example your textbook or tutorial letters. You are not allowed to consult any
third party for the duration of the exam session.
2. This paper consists of two (2) questions with subsections.
3. You are strongly advised to carefully read the required before attempting the questions concerned.
4. All questions and sub-sections must be answered.
5. Each sub-section must be commenced on a new (separate) page.
6. All workings, where applicable, must be shown.
7. Include (type/write) your student number in the document/answer file.
Open Rubric
Page 2 of 15
MAC3761 EXAMINATION
OCT/NOV 2023
Honesty Declaration:
By submitting my solution to the exam, I declare that:
I know what plagiarism is, that plagiarism is wrong and that disciplinary steps can be taken against me
if I am found guilty of plagiarism.
This solution, submitted by myself, is my own work.
I have not assisted any other student in any manner, and I have not had the assistance of any other
person, in completing this exam.
I will not assist any other student in any manner, and I will not obtain the assistance of any other
person, in completing this exam.
I know that if I am found to be in violation of this declaration, I will have to face a disciplinary hearing.
Please note: By submitting your solution, you automatically declare that you adhere to all the above
with regards to this specific assessment.
3. PRESCRIPTION DIVISION
The Division manufactures and sells three types of medicine, Codyl, Diphdol and Enpayne in
targeted therapeutic areas for patients consulting healthcare professionals, where prescriptions
are generally required. Codyl is for the relief of mild to moderate pain of inflammatory origin with
or without fever. Codyl is also sold internally to the Over-the-Counter Division where it is mixed
with other medicines and ingredients to create a new type of medicine for short-term pain relief
that is easily accessible over the counter to many customers. Codyl is currently sold to the Over-
the-Counter Division at the same price as to external customers, but the divisions want to
negotiate the transfer price in the future. Diphdol is a capsule for the relief of moderately severe
pain and short-term anxiety. Enpayne is an injection used for pain during a certain medical
procedure (local anaesthesia).
The following information relates to the budgeted selling price and costs per unit for the year
ending 30 September 2024. Information on budgeted machine hours per unit and the expected
sales demand is also provided below.
Expected total sales demand 400 000 350 000 250 000
(a) Critically evaluate the remuneration policy of Appleday with reference to its (6)
manufacturing divisions. [No calculations are required.]
(b) Determine whether the Consumer Division qualifies for any performance bonuses for (8)
the year ended 30 September 2023.
(c) Calculate the following variances for the Consumer Division for the year ended
30 September 2023 assuming that a standard costing system is in place, and discuss
possible reasons for such variances:
i. Direct labour rate variance – BioMade only (3 marks for calculation; 1 mark for
comment).
ii. Fixed manufacturing overhead volume variance (3 marks for calculation; 1 mark
for comment).
iii. Sales mix variance – BioMade only, assuming a standard gross profit of
R9,10 per unit of BioMade (3 marks for calculation; 1 mark for comment). (12)
(d) Discuss two ethical concerns that the Appleday management team may have when it (4)
comes to the Consumer Division.
(e) Discuss three non-financial performance measures that can be used in managing and (3)
measuring customer satisfaction for the Consumer Division.
(f) Determine the Prescription Division’s budgeted optimal production mix for the financial (12)
year ending 30 September 2024.
(g) Discuss factors that the Prescription Division will have to consider in proposing an (5)
internal selling price of the Codyl product supplied to the Over-the-Counter Division in
future transfer price negotiations. [No calculations are required.]
(vi) Trade payables relate to amounts owed to creditors for inventory purchased and will be
settled within a year.
Below is the detailed Earnings Before Interest and Tax (EBIT) of AKHA Traders for the year ended
30 September 2023:
Additional information and other economic indicators for the 2023 financial year, and comparative
figures, are given below:
REQUIRED
For each subsection below, remember to:
• Where applicable, clearly show all your calculations in detail;
• Where necessary, indicate irrelevant amounts/adjustments with a R0 (nil-value);
• Where necessary, assume amounts are before tax, unless where otherwise stated; and
• Where applicable, use South African corporate taxation rate of 27%.
You are required to prepare a report to the Chief Financial officer in which you
address the following questions:
(a) Identify five key business risks that AKHA Traders needs to prioritise for the 2024
financial year and explain how these risks can be mitigated. [Consider the local and
global economic environment in your answer.] (10)
(b) Determine the capital structure of AKHA Traders based on book values at
30 September 2023, and provide possible reasons for movement in the calculations
between 2022 and 2023 financial years. [Calculations 3 marks; discussion 2 marks] (5)
(c) Calculate the weighted average cost of capital of AKHA Traders based on market values
at 30 September 2023. (10)
(d) Determine how the business cycle (cash conversion cycle) will change in the 2024
financial year, considering the proposed business model and the projected sales
increase. [Only calculations are required, and use closing balances where applicable] (6)
(e) Perform a valuation of the 51% equity stake in Amos Hardware (Pty) Ltd. Use any two
appropriate valuation methods for reasonableness and a comparability test. (15)
(f) Discuss four factors that the Management Committee will have to consider when
choosing the appropriate funding facility for the acquisition of Amos Hardware (Pty) Ltd.
[Your answer should consider, as a minimum, economic data, AKHA Traders’
financial information and the available facilities] (4)